Audrey Greenberg is an award-winning executive, board director, and strategic advisor known for building and scaling multi-billion-dollar enterprises across biotechnology, private equity, and real estate. With deep expertise in operations, finance, commercial strategy, and M&A, Audrey has raised over $1.5 billion in capital and driven transformative growth for companies at the intersection of science, technology, and manufacturing. As Founder and Chief Business Officer of the Center for Breakthrough Medicines (CBM), Audrey transformed a startup vision into one of the world’s leading cell and gene therapy CDMOs culminating in its acquisition by SK pharmteco. Now leading AG Capital Advisors, Audrey advises private equity firms, biotech innovators, and portfolio companies on scaling strategies, capital allocation, operational excellence, and global expansion. She serves on multiple public and private boards bringing governance expertise across sectors. Recognized as a Titan 100 Hall of Famer, Most Influential Philadelphian, and Medicine Maker Power Lister, Audrey is a sought-after speaker shaping conversations around advanced therapies, biomanufacturing innovation, and growth leadership. Committed to driving impact beyond the boardroom, she actively supports industry advancement through roles with Penn Medicine Abramson Cancer Center, Alliance for Regenerative Medicine, Ben Franklin Technology Partners, and Women in Advanced Therapies, mentoring the next generation of biotech leaders. Audrey brings a clear message to today’s CGT manufacturing challenge: "The future won’t be scaled by technology alone, it will be scaled by those who can unify fragmented processes, align commercial and operational strategy, and challenge the status quo of bespoke solutions. Advanced therapies don’t just need manufacturing, they need a business model that’s built to grow."